Palisade Bio (PALI) Capital Expenditures (2010 - 2022)

Palisade Bio (PALI) reported Capital Expenditures of $10000.0 for Q4 2022, up 900.0% quarter-over-quarter from $1000.0 in Q4 2020.

Palisade Bio (PALI) Capital Expenditures (2010 - 2022) Analysis & Trends

Palisade Bio (PALI) has 10 years of Capital Expenditures data on file, last reported at $10000.0 in Q4 2022.

Capital Expenditures for Q4 2022 came in at $10000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $10000.0 (changed 0.0% YoY), and the FY2023 annual result was $4000.0, down 60.0% from the prior year.
Capital Expenditures rose to $10000.0 in Q4 2022 per PALI's latest filing, from $1000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $10000.0 in Q4 2022 and troughed at -$1000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	133.40 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-63,220.27
10	Palisade Bio	391.02 Mn	261.45 Mn	-	-

Download Data